Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030344 | 0.93 | PDE5A (0.80) | PDE5APDE6C | |
| SCHEMBL6777498 | 0.89 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL2034968 | 0.82 | PDE5A (0.80) | PDE5APDE6C | |
| SCHEMBL6773176 | 0.82 | PDE5A (0.77) | PDE5APDE6C | |
| SCHEMBL2033129 | 0.81 | PDE5A (0.79) | PDE5APDE6C | |
| SCHEMBL2031422 | 0.81 | PDE5A (0.73) | PDE5APDE6C | |
| SCHEMBL2029530 | 0.81 | PDE5A (0.79) | PDE5APDE6C | |
| SCHEMBL2032524 | 0.80 | PDE5A (0.80) | PDE5APDE6C | |
| SCHEMBL2030610 | 0.80 | PDE5A (0.79) | PDE5APDE6C | |
| SCHEMBL2029327 | 0.80 | PDE5A (0.78) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943518-B2 | Inhibitors of phosphodiesterase type 5A for reducing skeletal muscle fatigue, edema, and damage in a patient having muscle fatigue due to increased age or exercise | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160263118-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-09-15 | — | — | US | disclosed |
| US-9387210-B2 | Inhibitors of phosphodiesterase type 5A for treating or preventing muscle disease or the symptoms thereof in a patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140005202-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-01-02 | — | — | US | disclosed |
| US-20110160219-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160219-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 21/4885 |
| US-20160263118-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 21/4885 |
| US-20140005202-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.